Virtual pulmonary rehabilitation approaches in patients with post COVID syndrome: a pilot study.

Publication date: Mar 18, 2024

The characteristics of optimal virtual pulmonary rehabilitation (PR) for individuals with post-COVID syndrome (PCS) have not been identified. This study aimed to assess the feasibility, safety, and satisfaction associated with a virtual PR program with the exercise component delivered through group or self-directed sessions. Adults with PCS-respiratory symptoms were randomly assigned to the video conference (PR) or self-directed (PR) group and completed an exercise program (aerobic, strengthening, and breathing exercises) three times/week for eight weeks. PR sessions were led by a physiotherapist via Zoom, whereas the PR group exercised individually following a pre-recorded video. Both groups received personalized exercise recommendations, education related to the condition, and a weekly follow up call. Satisfaction was assessed through a patient survey. Lung function, dyspnea, fatigue, sit-to-stand capacity, health-related quality of life, and participation were assessed pre- and post-PR. Fourteen PCS individuals (49 +/- 9 years, 86% females) completed 83% of the sessions. All participants were satisfied with information provided by the therapist and frequency of data submission, whereas most were satisfied with the frequency and duration of exercise sessions (88% in PR and 83% in PR). A higher proportion of participants in the PR (88%) were satisfied with the level of difficulty of exercises compared with the PR (67%), and 84% of the sample reported a positive impact of the program on their health. No adverse events were reported. Significant changes in sit-to-stand capacity (p = 0. 012, Cohen’s r = 0. 67) and questions related to fatigue (p = 0. 027, Cohen’s r = 0. 58), neurocognitive (p = 0. 045, Cohen’s r = 0. 53), and autonomic (p = 0. 024, Cohen’s r = 0. 60) domains of the DePaul Symptom Questionnaire short-form were also found between groups. Virtual PR with exercises delivered via video conference or pre-recorded video were feasible, safe, and well-received by individuals with PCS. NCT05003271 (first posted: 12/08/2021).

Open Access PDF

Concepts Keywords
Covid Adult
Dyspnea COVID-19
Pilot Fatigue
Therapist Female
Pilot Projects
Post-COVID syndrome
Pulmonary rehabilitation
Quality of Life


Type Source Name
disease MESH syndrome
disease IDO quality
disease VO frequency
disease IDO symptom
disease MESH Long Covid
pathway REACTOME Reproduction
disease VO Canada
disease MESH morbidity
disease MESH COVID 19
disease MESH respiratory diseases
disease VO effective
disease VO viable
disease MESH infection
disease VO device
disease IDO history
drug DRUGBANK Ranitidine
drug DRUGBANK Methionine
drug DRUGBANK Coenzyme M
disease VO nose
disease VO USA
drug DRUGBANK Trestolone
disease VO protocol
drug DRUGBANK Oxygen
disease MESH emergency
disease IDO process
disease IDO intervention
disease VO volume
disease MESH myalgic encephalomyelitis
disease VO population
drug DRUGBANK Nonoxynol-9
disease VO ReCOV
disease MESH reinfection
drug DRUGBANK Tropicamide
disease VO age
disease MESH Migraine
disease MESH Hypertension
disease MESH Asthma
pathway KEGG Asthma
disease MESH Hashimoto syndrome
disease MESH Tachycardia
disease MESH Heart murmur
disease MESH cognitive dysfunction
drug DRUGBANK Spinosad
disease MESH complications
drug DRUGBANK Cycloserine
disease VO organization
pathway KEGG Coronavirus disease
drug DRUGBANK Guanosine
disease MESH Return to work
disease MESH COPD
disease MESH idiopathic pulmonary fibrosis
disease MESH interstitial lung disease
disease VO effectiveness
disease MESH stroke
disease MESH lung diseases
drug DRUGBANK MK-212
disease MESH Musculoskeletal Pain
disease MESH anorexia nervosa
drug DRUGBANK D-Alanine
disease MESH chronic illness
drug DRUGBANK Ilex paraguariensis leaf
disease IDO country
drug DRUGBANK Sotalol

Original Article

(Visited 1 times, 1 visits today)